Industry Research Reports
Home > Reports > Service & Software > Global Multi-cancer Early Detection (MCED) Tests Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Global Multi-cancer Early Detection (MCED) Tests Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Industry: Service & Software
Published Date: 2025-07-24
Pages: 119 Pages
Report ld: 4799017
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Multi-cancer Early Detection (MCED) Tests Market Size(US$)
CAGR 2025-2031
19.7%
Market Size,2031
USD 3,081
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 1,047 million
Market Forecast in 2031(Value)
US$ 3,081 million
CAGR
19.7%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Multi-cancer Early Detection (MCED) Tests market size was US$ 875 million in 2024 and is forecast to a readjusted size of US$ 3081 million by 2031 with a CAGR of 19.7% during the forecast period 2025-2031.
The Multiple Cancer Early Detection (MCED) test is a blood test designed to detect multiple cancer types early, potentially before symptoms appear. Often referred to as liquid biopsies, these tests identify cancer signatures by analyzing circulating tumor DNA (ctDNA) and other biomarkers in the blood. While still under evaluation, the MCED test has the potential to revolutionize cancer screening because it has the potential to detect cancers not covered by current screening methods and increase overall early detection rates.
The North America Multi-cancer Early Detection (MCED) Tests market size was US$ million in 2024, while Europe was US$ million. The proportion of the North America was % in 2024, while Europe percentage was %, and it is predicted that Europe share will reach % in 2031, trailing a CAGR of % through the analysis period.
The global key players of Multi-cancer Early Detection (MCED) Tests include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life, Berry Genomics, Singlera Genomics, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In North America, in terms of revenue, in 2024, the top three players hold a share about %, while in Europe, top three players hold a share nearly %.
The global Multi-cancer Early Detection (MCED) Tests market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
MARKET SEGMENTATION
By Company
- Guardant Health
- Exact Sciences
- Freenome
- Epiginomics AG
- Bio-techne
- ThriveEarlier Detection
- GRAIL, Inc.
- CellMax life
- Berry Genomics
- Singlera Genomics
- Geneseeq
- BGI Genomics
- Burning Rock Biotech Limited
- New Horizon Health Limited
- Yeasen Bio
- Hangzhou Aoru Biotech
- Amoy Diagnostics Co., Ltd.
- Genetron Health
- AnchorDx
- Surexam Bio-Tech Co.,Ltd.
- HaploX
- HefeiLaierBiotechnologyCo.,Ltd
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- ctDNA Detection
- CTC Detection
- Exosome Detection
Segment by Application
- Medical Institutions
- Physical Examination Centers
Segment by Category
- IVD（In Vitro Diagnostics）
- LDT (Laboratory Developed Test)
CHAPTER OUTLINE
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Multi-cancer Early Detection (MCED) Tests market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., CTC Detection in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Physical Examination Centers in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Multi-cancer Early Detection (MCED) Tests value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 ctDNA Detection
1.2.3 CTC Detection
1.2.4 Exosome Detection
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Medical Institutions
1.3.3 Physical Examination Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Multi-cancer Early Detection (MCED) Tests Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Region (2020-2025)
2.4 Global Multi-cancer Early Detection (MCED) Tests Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Multi-cancer Early Detection (MCED) Tests Market Size and Prospective (2020-2031)
2.5.2 Europe Multi-cancer Early Detection (MCED) Tests Market Size and Prospective (2020-2031)
2.5.3 China Multi-cancer Early Detection (MCED) Tests Market Size and Prospective (2020-2031)
2.5.4 Japan Multi-cancer Early Detection (MCED) Tests Market Size and Prospective (2020-2031)
2.5.5 Southeast Asia Multi-cancer Early Detection (MCED) Tests Market Size and Prospective (2020-2031)
2.5.6 India Multi-cancer Early Detection (MCED) Tests Market Size and Prospective (2020-2031)
2.5.7 South America Multi-cancer Early Detection (MCED) Tests Market Size and Prospective (2020-2031)
2.5.8 Middle East Multi-cancer Early Detection (MCED) Tests Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Multi-cancer Early Detection (MCED) Tests Historic Market Size by Type (2020-2025)
3.2 Global Multi-cancer Early Detection (MCED) Tests Forecasted Market Size by Type (2026-2031)
3.3 Different Types Multi-cancer Early Detection (MCED) Tests Representative Players
4 Breakdown Data by Application
4.1 Global Multi-cancer Early Detection (MCED) Tests Historic Market Size by Application (2020-2025)
4.2 Global Multi-cancer Early Detection (MCED) Tests Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Multi-cancer Early Detection (MCED) Tests Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Multi-cancer Early Detection (MCED) Tests Players by Revenue (2020-2025)
5.1.2 Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Multi-cancer Early Detection (MCED) Tests Revenue
5.4 Global Multi-cancer Early Detection (MCED) Tests Market Concentration Analysis
5.4.1 Global Multi-cancer Early Detection (MCED) Tests Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Multi-cancer Early Detection (MCED) Tests Revenue in 2024
5.5 Global Key Players of Multi-cancer Early Detection (MCED) Tests Head office and Area Served
5.6 Global Key Players of Multi-cancer Early Detection (MCED) Tests, Product and Application
5.7 Global Key Players of Multi-cancer Early Detection (MCED) Tests, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025)
6.1.2.2 North America Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025)
6.1.3.2 North America Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025)
6.2.2.2 Europe Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025)
6.2.3.2 Europe Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025)
6.3.2.2 China Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025)
6.3.3.2 China Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025)
6.4.2.2 Japan Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025)
6.4.3.2 Japan Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
6.5 Southeast Asia Market: Players, Segments and Downstream
6.5.1 Southeast Asia Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025)
6.5.2 Southeast Asia Market Size by Type
6.5.2.1 Southeast Asia Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025)
6.5.2.2 Southeast Asia Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
6.5.3 Southeast Asia Market Size by Application
6.5.3.1 Southeast Asia Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025)
6.5.3.2 Southeast Asia Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
6.5.4 Southeast Asia Market Trend and Opportunities
6.6 India Market: Players, Segments and Downstream
6.6.1 India Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025)
6.6.2 India Market Size by Type
6.6.2.1 India Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025)
6.6.2.2 India Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
6.6.3 India Market Size by Application
6.6.3.1 India Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025)
6.6.3.2 India Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
6.6.4 India Market Trend and Opportunities
7 Key Players Profiles
7.1 Guardant Health
7.1.1 Guardant Health Company Details
7.1.2 Guardant Health Business Overview
7.1.3 Guardant Health Multi-cancer Early Detection (MCED) Tests Introduction
7.1.4 Guardant Health Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.1.5 Guardant Health Recent Development
7.2 Exact Sciences
7.2.1 Exact Sciences Company Details
7.2.2 Exact Sciences Business Overview
7.2.3 Exact Sciences Multi-cancer Early Detection (MCED) Tests Introduction
7.2.4 Exact Sciences Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.2.5 Exact Sciences Recent Development
7.3 Freenome
7.3.1 Freenome Company Details
7.3.2 Freenome Business Overview
7.3.3 Freenome Multi-cancer Early Detection (MCED) Tests Introduction
7.3.4 Freenome Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.3.5 Freenome Recent Development
7.4 Epiginomics AG
7.4.1 Epiginomics AG Company Details
7.4.2 Epiginomics AG Business Overview
7.4.3 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Introduction
7.4.4 Epiginomics AG Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.4.5 Epiginomics AG Recent Development
7.5 Bio-techne
7.5.1 Bio-techne Company Details
7.5.2 Bio-techne Business Overview
7.5.3 Bio-techne Multi-cancer Early Detection (MCED) Tests Introduction
7.5.4 Bio-techne Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.5.5 Bio-techne Recent Development
7.6 ThriveEarlier Detection
7.6.1 ThriveEarlier Detection Company Details
7.6.2 ThriveEarlier Detection Business Overview
7.6.3 ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Introduction
7.6.4 ThriveEarlier Detection Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.6.5 ThriveEarlier Detection Recent Development
7.7 GRAIL, Inc.
7.7.1 GRAIL, Inc. Company Details
7.7.2 GRAIL, Inc. Business Overview
7.7.3 GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Introduction
7.7.4 GRAIL, Inc. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.7.5 GRAIL, Inc. Recent Development
7.8 CellMax life
7.8.1 CellMax life Company Details
7.8.2 CellMax life Business Overview
7.8.3 CellMax life Multi-cancer Early Detection (MCED) Tests Introduction
7.8.4 CellMax life Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.8.5 CellMax life Recent Development
7.9 Berry Genomics
7.9.1 Berry Genomics Company Details
7.9.2 Berry Genomics Business Overview
7.9.3 Berry Genomics Multi-cancer Early Detection (MCED) Tests Introduction
7.9.4 Berry Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.9.5 Berry Genomics Recent Development
7.10 Singlera Genomics
7.10.1 Singlera Genomics Company Details
7.10.2 Singlera Genomics Business Overview
7.10.3 Singlera Genomics Multi-cancer Early Detection (MCED) Tests Introduction
7.10.4 Singlera Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.10.5 Singlera Genomics Recent Development
7.11 Geneseeq
7.11.1 Geneseeq Company Details
7.11.2 Geneseeq Business Overview
7.11.3 Geneseeq Multi-cancer Early Detection (MCED) Tests Introduction
7.11.4 Geneseeq Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.11.5 Geneseeq Recent Development
7.12 BGI Genomics
7.12.1 BGI Genomics Company Details
7.12.2 BGI Genomics Business Overview
7.12.3 BGI Genomics Multi-cancer Early Detection (MCED) Tests Introduction
7.12.4 BGI Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.12.5 BGI Genomics Recent Development
7.13 Burning Rock Biotech Limited
7.13.1 Burning Rock Biotech Limited Company Details
7.13.2 Burning Rock Biotech Limited Business Overview
7.13.3 Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Introduction
7.13.4 Burning Rock Biotech Limited Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.13.5 Burning Rock Biotech Limited Recent Development
7.14 New Horizon Health Limited
7.14.1 New Horizon Health Limited Company Details
7.14.2 New Horizon Health Limited Business Overview
7.14.3 New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Introduction
7.14.4 New Horizon Health Limited Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.14.5 New Horizon Health Limited Recent Development
7.15 Yeasen Bio
7.15.1 Yeasen Bio Company Details
7.15.2 Yeasen Bio Business Overview
7.15.3 Yeasen Bio Multi-cancer Early Detection (MCED) Tests Introduction
7.15.4 Yeasen Bio Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.15.5 Yeasen Bio Recent Development
7.16 Hangzhou Aoru Biotech
7.16.1 Hangzhou Aoru Biotech Company Details
7.16.2 Hangzhou Aoru Biotech Business Overview
7.16.3 Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Introduction
7.16.4 Hangzhou Aoru Biotech Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.16.5 Hangzhou Aoru Biotech Recent Development
7.17 Amoy Diagnostics Co., Ltd.
7.17.1 Amoy Diagnostics Co., Ltd. Company Details
7.17.2 Amoy Diagnostics Co., Ltd. Business Overview
7.17.3 Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Introduction
7.17.4 Amoy Diagnostics Co., Ltd. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.17.5 Amoy Diagnostics Co., Ltd. Recent Development
7.18 Genetron Health
7.18.1 Genetron Health Company Details
7.18.2 Genetron Health Business Overview
7.18.3 Genetron Health Multi-cancer Early Detection (MCED) Tests Introduction
7.18.4 Genetron Health Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.18.5 Genetron Health Recent Development
7.19 AnchorDx
7.19.1 AnchorDx Company Details
7.19.2 AnchorDx Business Overview
7.19.3 AnchorDx Multi-cancer Early Detection (MCED) Tests Introduction
7.19.4 AnchorDx Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.19.5 AnchorDx Recent Development
7.20 Surexam Bio-Tech Co.,Ltd.
7.20.1 Surexam Bio-Tech Co.,Ltd. Company Details
7.20.2 Surexam Bio-Tech Co.,Ltd. Business Overview
7.20.3 Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Introduction
7.20.4 Surexam Bio-Tech Co.,Ltd. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.20.5 Surexam Bio-Tech Co.,Ltd. Recent Development
7.21 HaploX
7.21.1 HaploX Company Details
7.21.2 HaploX Business Overview
7.21.3 HaploX Multi-cancer Early Detection (MCED) Tests Introduction
7.21.4 HaploX Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.21.5 HaploX Recent Development
7.22 HefeiLaierBiotechnologyCo.,Ltd
7.22.1 HefeiLaierBiotechnologyCo.,Ltd Company Details
7.22.2 HefeiLaierBiotechnologyCo.,Ltd Business Overview
7.22.3 HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Introduction
7.22.4 HefeiLaierBiotechnologyCo.,Ltd Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
7.22.5 HefeiLaierBiotechnologyCo.,Ltd Recent Development
8 Multi-cancer Early Detection (MCED) Tests Market Dynamics
8.1 Multi-cancer Early Detection (MCED) Tests Industry Trends
8.2 Multi-cancer Early Detection (MCED) Tests Market Drivers
8.3 Multi-cancer Early Detection (MCED) Tests Market Challenges
8.4 Multi-cancer Early Detection (MCED) Tests Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Multi-cancer Early Detection (MCED) Tests Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Multi-cancer Early Detection (MCED) Tests Revenue Share by Region (2020-2025)
Table 6. Global Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Multi-cancer Early Detection (MCED) Tests Revenue Share Forecast by Region (2026-2031)
Table 8. Global Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Type (2020-2025)
Table 10. Global Multi-cancer Early Detection (MCED) Tests Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Application (2020-2025)
Table 15. Global Multi-cancer Early Detection (MCED) Tests Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Multi-cancer Early Detection (MCED) Tests Application
Table 18. Global Multi-cancer Early Detection (MCED) Tests Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Multi-cancer Early Detection (MCED) Tests Market Share by Players (2020-2025)
Table 20. Global Top Multi-cancer Early Detection (MCED) Tests Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multi-cancer Early Detection (MCED) Tests as of 2024)
Table 21. Ranking of Global Top Multi-cancer Early Detection (MCED) Tests Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Multi-cancer Early Detection (MCED) Tests Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Multi-cancer Early Detection (MCED) Tests, Headquarters and Area Served
Table 24. Global Key Players of Multi-cancer Early Detection (MCED) Tests, Product and Application
Table 25. Global Key Players of Multi-cancer Early Detection (MCED) Tests, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Company (2020-2025)
Table 29. North America Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Company (2020-2025)
Table 33. Europe Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Company (2020-2025)
Table 37. China Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Company (2020-2025)
Table 41. Japan Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025) & (US$ Million)
Table 43. Southeast Asia Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025) & (US$ Million)
Table 44. Southeast Asia Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Company (2020-2025)
Table 45. Southeast Asia Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025) & (US$ Million)
Table 46. Southeast Asia Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025) & (US$ Million)
Table 47. India Multi-cancer Early Detection (MCED) Tests Revenue by Company (2020-2025) & (US$ Million)
Table 48. India Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Company (2020-2025)
Table 49. India Multi-cancer Early Detection (MCED) Tests Market Size by Type (2020-2025) & (US$ Million)
Table 50. India Multi-cancer Early Detection (MCED) Tests Market Size by Application (2020-2025) & (US$ Million)
Table 51. Guardant Health Company Details
Table 52. Guardant Health Business Overview
Table 53. Guardant Health Multi-cancer Early Detection (MCED) Tests Product
Table 54. Guardant Health Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 55. Guardant Health Recent Development
Table 56. Exact Sciences Company Details
Table 57. Exact Sciences Business Overview
Table 58. Exact Sciences Multi-cancer Early Detection (MCED) Tests Product
Table 59. Exact Sciences Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 60. Exact Sciences Recent Development
Table 61. Freenome Company Details
Table 62. Freenome Business Overview
Table 63. Freenome Multi-cancer Early Detection (MCED) Tests Product
Table 64. Freenome Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 65. Freenome Recent Development
Table 66. Epiginomics AG Company Details
Table 67. Epiginomics AG Business Overview
Table 68. Epiginomics AG Multi-cancer Early Detection (MCED) Tests Product
Table 69. Epiginomics AG Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 70. Epiginomics AG Recent Development
Table 71. Bio-techne Company Details
Table 72. Bio-techne Business Overview
Table 73. Bio-techne Multi-cancer Early Detection (MCED) Tests Product
Table 74. Bio-techne Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 75. Bio-techne Recent Development
Table 76. ThriveEarlier Detection Company Details
Table 77. ThriveEarlier Detection Business Overview
Table 78. ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Product
Table 79. ThriveEarlier Detection Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 80. ThriveEarlier Detection Recent Development
Table 81. GRAIL, Inc. Company Details
Table 82. GRAIL, Inc. Business Overview
Table 83. GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Product
Table 84. GRAIL, Inc. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 85. GRAIL, Inc. Recent Development
Table 86. CellMax life Company Details
Table 87. CellMax life Business Overview
Table 88. CellMax life Multi-cancer Early Detection (MCED) Tests Product
Table 89. CellMax life Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 90. CellMax life Recent Development
Table 91. Berry Genomics Company Details
Table 92. Berry Genomics Business Overview
Table 93. Berry Genomics Multi-cancer Early Detection (MCED) Tests Product
Table 94. Berry Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 95. Berry Genomics Recent Development
Table 96. Singlera Genomics Company Details
Table 97. Singlera Genomics Business Overview
Table 98. Singlera Genomics Multi-cancer Early Detection (MCED) Tests Product
Table 99. Singlera Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 100. Singlera Genomics Recent Development
Table 101. Geneseeq Company Details
Table 102. Geneseeq Business Overview
Table 103. Geneseeq Multi-cancer Early Detection (MCED) Tests Product
Table 104. Geneseeq Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 105. Geneseeq Recent Development
Table 106. BGI Genomics Company Details
Table 107. BGI Genomics Business Overview
Table 108. BGI Genomics Multi-cancer Early Detection (MCED) Tests Product
Table 109. BGI Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 110. BGI Genomics Recent Development
Table 111. Burning Rock Biotech Limited Company Details
Table 112. Burning Rock Biotech Limited Business Overview
Table 113. Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Product
Table 114. Burning Rock Biotech Limited Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 115. Burning Rock Biotech Limited Recent Development
Table 116. New Horizon Health Limited Company Details
Table 117. New Horizon Health Limited Business Overview
Table 118. New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Product
Table 119. New Horizon Health Limited Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 120. New Horizon Health Limited Recent Development
Table 121. Yeasen Bio Company Details
Table 122. Yeasen Bio Business Overview
Table 123. Yeasen Bio Multi-cancer Early Detection (MCED) Tests Product
Table 124. Yeasen Bio Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 125. Yeasen Bio Recent Development
Table 126. Hangzhou Aoru Biotech Company Details
Table 127. Hangzhou Aoru Biotech Business Overview
Table 128. Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Product
Table 129. Hangzhou Aoru Biotech Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 130. Hangzhou Aoru Biotech Recent Development
Table 131. Amoy Diagnostics Co., Ltd. Company Details
Table 132. Amoy Diagnostics Co., Ltd. Business Overview
Table 133. Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Product
Table 134. Amoy Diagnostics Co., Ltd. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 135. Amoy Diagnostics Co., Ltd. Recent Development
Table 136. Genetron Health Company Details
Table 137. Genetron Health Business Overview
Table 138. Genetron Health Multi-cancer Early Detection (MCED) Tests Product
Table 139. Genetron Health Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 140. Genetron Health Recent Development
Table 141. AnchorDx Company Details
Table 142. AnchorDx Business Overview
Table 143. AnchorDx Multi-cancer Early Detection (MCED) Tests Product
Table 144. AnchorDx Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 145. AnchorDx Recent Development
Table 146. Surexam Bio-Tech Co.,Ltd. Company Details
Table 147. Surexam Bio-Tech Co.,Ltd. Business Overview
Table 148. Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Product
Table 149. Surexam Bio-Tech Co.,Ltd. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 150. Surexam Bio-Tech Co.,Ltd. Recent Development
Table 151. HaploX Company Details
Table 152. HaploX Business Overview
Table 153. HaploX Multi-cancer Early Detection (MCED) Tests Product
Table 154. HaploX Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 155. HaploX Recent Development
Table 156. HefeiLaierBiotechnologyCo.,Ltd Company Details
Table 157. HefeiLaierBiotechnologyCo.,Ltd Business Overview
Table 158. HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Product
Table 159. HefeiLaierBiotechnologyCo.,Ltd Revenue in Multi-cancer Early Detection (MCED) Tests Business (2020-2025) & (US$ Million)
Table 160. HefeiLaierBiotechnologyCo.,Ltd Recent Development
Table 161. Multi-cancer Early Detection (MCED) Tests Market Trends
Table 162. Multi-cancer Early Detection (MCED) Tests Market Drivers
Table 163. Multi-cancer Early Detection (MCED) Tests Market Challenges
Table 164. Multi-cancer Early Detection (MCED) Tests Market Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Multi-cancer Early Detection (MCED) Tests Product Picture
Figure 2. Global Multi-cancer Early Detection (MCED) Tests Market Share by Type: 2024 VS 2031
Figure 3. ctDNA Detection Features
Figure 4. CTC Detection Features
Figure 5. Exosome Detection Features
Figure 6. Global Multi-cancer Early Detection (MCED) Tests Market Share by Application: 2024 VS 2031
Figure 7. Medical Institutions
Figure 8. Physical Examination Centers
Figure 9. Multi-cancer Early Detection (MCED) Tests Report Years Considered
Figure 10. Global Multi-cancer Early Detection (MCED) Tests Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 11. Global Multi-cancer Early Detection (MCED) Tests Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Region: 2020 VS 2024
Figure 13. North America Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) Growth Rate (2020-2031)
Figure 14. Europe Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. China Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Japan Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Southeast Asia Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. India Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) Growth Rate (2020-2031)
Figure 19. South America Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Middle East Multi-cancer Early Detection (MCED) Tests Revenue (US$ Million) Growth Rate (2020-2031)
Figure 21. Global Multi-cancer Early Detection (MCED) Tests Market Share by Players in 2024
Figure 22. Global Top Multi-cancer Early Detection (MCED) Tests Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multi-cancer Early Detection (MCED) Tests as of 2024)
Figure 23. The Top 10 and 5 Players Market Share by Multi-cancer Early Detection (MCED) Tests Revenue in 2024
Figure 24. North America Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
Figure 25. North America Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
Figure 26. Europe Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
Figure 27. Europe Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
Figure 28. China Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
Figure 29. China Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
Figure 30. Japan Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
Figure 31. Japan Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
Figure 32. Southeast Asia Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
Figure 33. Southeast Asia Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
Figure 34. India Multi-cancer Early Detection (MCED) Tests Market Share by Type (2020-2025)
Figure 35. India Multi-cancer Early Detection (MCED) Tests Market Share by Application (2020-2025)
Figure 36. Guardant Health Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 37. Exact Sciences Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 38. Freenome Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 39. Epiginomics AG Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 40. Bio-techne Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 41. ThriveEarlier Detection Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 42. GRAIL, Inc. Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 43. CellMax life Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 44. Berry Genomics Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 45. Singlera Genomics Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 46. Geneseeq Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 47. BGI Genomics Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 48. Burning Rock Biotech Limited Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 49. New Horizon Health Limited Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 50. Yeasen Bio Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 51. Hangzhou Aoru Biotech Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 52. Amoy Diagnostics Co., Ltd. Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 53. Genetron Health Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 54. AnchorDx Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 55. Surexam Bio-Tech Co.,Ltd. Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 56. HaploX Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 57. HefeiLaierBiotechnologyCo.,Ltd Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What is the annual compound growth rate of the global Multi-cancer Early Detection (MCED) Tests market size from 2025 to 2031?
The annual compound growth rate of the global Multi-cancer Early Detection (MCED) Tests market is 19.7% 2025 to 2031.
What was the global market size of Multi-cancer Early Detection (MCED) Tests in 2025?
Which region is expected to have the highest market share?
Which companies rank high in the global Multi-cancer Early Detection (MCED) Tests market?
What was the global market size of Multi-cancer Early Detection (MCED) Tests in 2031?
Related Reports
Global Multi-cancer Early Detection (MCED) Tests Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Multi-cancer Early Detection (MCED) Tests market is projected to grow from US$ 1047 million in 2025 to US$ 3627 million by 2032, at a CAGR of 19.7% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-12
Pages: 162
USD 4900.00
(Single User License)
Global Multi-cancer Early Detection (MCED) Tests Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Multi-cancer Early Detection (MCED) Tests market size was US$ 1047 million in 2025 and is forecast to reach a readjusted size of US$ 3627 million by 2032 with a CAGR of 19.7% during the forecast period 2026-2032.
Published Date: 2026-03-12
Pages: 113
USD 4250.00
(Single User License)
Global Multi-cancer Early Detection (MCED) Tests Market Research Report 2026
The global Multi-cancer Early Detection (MCED) Tests market was valued at US$ 1047 million in 2025 and is anticipated to reach US$ 3627 million by 2032, at a CAGR of 19.7% from 2026 to 2032.
Published Date: 2026-03-12
Pages: 157
USD 2900.00
(Single User License)
Multi-cancer Early Detection (MCED) Tests - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Multi-cancer Early Detection (MCED) Tests was estimated to be worth US$ 1047 million in 2025 and is projected to reach US$ 3627 million, growing at a CAGR of 19.7% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 143
USD 3950.00
(Single User License)
Multi-cancer Early Detection (MCED) Tests - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Multi-cancer Early Detection (MCED) Tests was estimated to be worth US$ 875 million in 2024 and is forecast to a readjusted size of US$ 3081 million by 2031 with a CAGR of 19.7% during the forecast period 2025-2031.
Published Date: 2025-07-24
Pages: 148
USD 3950.00
(Single User License)
Global Multi-cancer Early Detection (MCED) Tests Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Multi-cancer Early Detection (MCED) Tests market is projected to grow from US$ 875 million in 2024 to US$ 3081 million by 2031, at a CAGR of 19.7% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-07-24
Pages: 174
USD 4900.00
(Single User License)
Global Multi-cancer Early Detection (MCED) Tests Market Research Report 2025
The global market for Multi-cancer Early Detection (MCED) Tests was valued at US$ 875 million in the year 2024 and is projected to reach a revised size of US$ 3081 million by 2031, growing at a CAGR of 19.7% during the forecast period.
Published Date: 2025-07-24
Pages: 109
USD 2900.00
(Single User License)
Global Multi-cancer Early Detection (MCED) Tests Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Multi-cancer Early Detection (MCED) Tests market is projected to grow from US$ 1047 million in 2025 to US$ 3627 million by 2032, at a CAGR of 19.7% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-12
Pages: 162
USD 4900.00 (Single User License)Global Multi-cancer Early Detection (MCED) Tests Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Multi-cancer Early Detection (MCED) Tests market size was US$ 1047 million in 2025 and is forecast to reach a readjusted size of US$ 3627 million by 2032 with a CAGR of 19.7% during the forecast period 2026-2032.
Published: 2026-03-12
Pages: 113
USD 4250.00 (Single User License)Global Multi-cancer Early Detection (MCED) Tests Market Research Report 2026
The global Multi-cancer Early Detection (MCED) Tests market was valued at US$ 1047 million in 2025 and is anticipated to reach US$ 3627 million by 2032, at a CAGR of 19.7% from 2026 to 2032.
Published: 2026-03-12
Pages: 157
USD 2900.00 (Single User License)Multi-cancer Early Detection (MCED) Tests - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Multi-cancer Early Detection (MCED) Tests was estimated to be worth US$ 1047 million in 2025 and is projected to reach US$ 3627 million, growing at a CAGR of 19.7% from 2026 to 2032.
Published: 2026-03-09
Pages: 143
USD 3950.00 (Single User License)Multi-cancer Early Detection (MCED) Tests - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Multi-cancer Early Detection (MCED) Tests was estimated to be worth US$ 875 million in 2024 and is forecast to a readjusted size of US$ 3081 million by 2031 with a CAGR of 19.7% during the forecast period 2025-2031.
Published: 2025-07-24
Pages: 148
USD 3950.00 (Single User License)Global Multi-cancer Early Detection (MCED) Tests Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Multi-cancer Early Detection (MCED) Tests market is projected to grow from US$ 875 million in 2024 to US$ 3081 million by 2031, at a CAGR of 19.7% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-07-24
Pages: 174
USD 4900.00 (Single User License)Global Multi-cancer Early Detection (MCED) Tests Market Research Report 2025
The global market for Multi-cancer Early Detection (MCED) Tests was valued at US$ 875 million in the year 2024 and is projected to reach a revised size of US$ 3081 million by 2031, growing at a CAGR of 19.7% during the forecast period.
Published: 2025-07-24
Pages: 109
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4250.00
USD 6375.00
USD 8500.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now